TY - JOUR
T1 - Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant Gliomas
AU - Unruh, Dusten
AU - Mirkov, Snezana
AU - Wray, Brian
AU - Drumm, Michael
AU - Lamano, Jonathan
AU - Li, Yuping D.
AU - Haider, Qazi F.
AU - Javier, Rodrigo
AU - McCortney, Kathleen
AU - Saratsis, Amanda
AU - Scholtens, Denise M.
AU - Sarkaria, Jann N.
AU - David James, C.
AU - Horbinski, Craig
N1 - Funding Information:
We thank Dr. Hai Yan for the TB09 cells, Lisa Magnusson for her assistance with the glioma PDX models, and Alicia Steffens for IHC and histochemical staining. This work was supported by NIH grants K08CA155764 and R01NS102669 (to C. Horbinski). D. Unruh was supported by NIH grants T32CA070085 and F32CA216996. C. Horbinski, D.M. Scholtens, and C.D. James were also supported by the Northwestern SPORE in Brain Cancer P50CA221747. The Mayo Clinic Brain Tumor Patient-Derived Xenograft National Resource is supported by Mayo Clinic, the Mayo SPORE in Brain Cancer P50CA108961 and NIH grant R24NS92940. Histology and fluorescent microscopy services were provided by the Mouse Histology and Phenotyping Laboratory and the Center for Advanced Microscopy/Nikon Imaging Center, respectively; both are supported by NCI P30CA060553 awarded to the Robert H. Lurie Comprehensive Cancer Center.
Funding Information:
We thank Dr. Hai Yan for the TB09 cells, Lisa Magnusson for her assistance with the glioma PDX models, and Alicia Steffens for IHC and histochemical staining. This work was supported by NIH grants K08CA155764 and R01NS102669 (to C. Horbinski). D. Unruh was supported by NIH grants T32CA070085 and F32CA216996. C. Horbinski, D.M. Scholtens, and C.D. James were also supported by the Northwestern SPORE in Brain Cancer P50CA221747. The Mayo Clinic Brain Tumor Patient-Derived Xenograft National Resource is supported by Mayo Clinic, the Mayo SPORE in Brain Cancer P50CA108961 and NIH grant R24NS92940. Histology and fluorescent microscopy services were provided by the Mouse Histology and Phenotyping Laboratory and the Center for Advanced Microscopy/Nikon Imaging Center,
Publisher Copyright:
© 2018 American Association for Cancer Research.
PY - 2019/1/15
Y1 - 2019/1/15
N2 - Purpose: Gliomas with isocitrate dehydrogenase 1 mutations (IDH1 mut ) are less aggressive than IDH1 wild-type (IDH1 wt ) gliomas and have global genomic hypermethylation. Yet it is unclear how specific hypermethylation events contribute to the IDH1 mut phenotype. Previously, we showed that the gene encoding the procoagulant tissue factor (TF), F3, is among the most hypermethylated and downregulated genes in IDH1 mut gliomas, correlating with greatly reduced thrombosis in patients with IDH1 mut glioma. Because TF also increases the aggressiveness of many cancers, the current study explored the contribution of TF suppression to the reduced malignancy of IDH1 mut gliomas. Experimental Design: TF expression was manipulated in patient-derived IDH1 mut and IDH1 wt glioma cells, followed by evaluation of in vitro and in vivo behavior and analyses of cell signaling pathways. Results: A demethylating agent, decitabine, increased F3 transcription and TF-dependent coagulative activity in IDH1 mut cells, but not in IDH1 wt cells. TF induction enhanced the proliferation, invasion, and colony formation of IDH1 mut cells, and increased the intracranial engraftment of IDH1 mut GBM164 from 0% to 100% (P ¼ 0.0001). Conversely, TF knockdown doubled the median survival of mice engrafted with IDH1 wt /EGFRvIII amp GBM6, and caused complete regression of IDH1 wt /EGFR amp GBM12 (P ¼ 0.001). In vitro and in vivo effects were linked to activation of receptor tyrosine kinases (RTK) by TF through a Src-dependent intracellular pathway, even when extracellular RTK stimulation was blocked. TF stimulated invasion predominately through upregulation of b-catenin. Conclusions: These data show that TF suppression is a component of IDH1 mut glioma behavior, and that it may therefore be an attractive target against IDH1 wt gliomas.
AB - Purpose: Gliomas with isocitrate dehydrogenase 1 mutations (IDH1 mut ) are less aggressive than IDH1 wild-type (IDH1 wt ) gliomas and have global genomic hypermethylation. Yet it is unclear how specific hypermethylation events contribute to the IDH1 mut phenotype. Previously, we showed that the gene encoding the procoagulant tissue factor (TF), F3, is among the most hypermethylated and downregulated genes in IDH1 mut gliomas, correlating with greatly reduced thrombosis in patients with IDH1 mut glioma. Because TF also increases the aggressiveness of many cancers, the current study explored the contribution of TF suppression to the reduced malignancy of IDH1 mut gliomas. Experimental Design: TF expression was manipulated in patient-derived IDH1 mut and IDH1 wt glioma cells, followed by evaluation of in vitro and in vivo behavior and analyses of cell signaling pathways. Results: A demethylating agent, decitabine, increased F3 transcription and TF-dependent coagulative activity in IDH1 mut cells, but not in IDH1 wt cells. TF induction enhanced the proliferation, invasion, and colony formation of IDH1 mut cells, and increased the intracranial engraftment of IDH1 mut GBM164 from 0% to 100% (P ¼ 0.0001). Conversely, TF knockdown doubled the median survival of mice engrafted with IDH1 wt /EGFRvIII amp GBM6, and caused complete regression of IDH1 wt /EGFR amp GBM12 (P ¼ 0.001). In vitro and in vivo effects were linked to activation of receptor tyrosine kinases (RTK) by TF through a Src-dependent intracellular pathway, even when extracellular RTK stimulation was blocked. TF stimulated invasion predominately through upregulation of b-catenin. Conclusions: These data show that TF suppression is a component of IDH1 mut glioma behavior, and that it may therefore be an attractive target against IDH1 wt gliomas.
UR - http://www.scopus.com/inward/record.url?scp=85060058512&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060058512&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-18-1222
DO - 10.1158/1078-0432.CCR-18-1222
M3 - Article
C2 - 30266764
AN - SCOPUS:85060058512
SN - 1078-0432
VL - 25
SP - 747
EP - 759
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 2
ER -